VANCOUVER, BC, June 16, 2020 /CNW/ - Sirona Biochem Corp. (TSXV:
SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is
pleased to announce that it has made its first shipment of
compound, TFC-1067, to industry leader Rodan + Fields, LLC
("Rodan + Fields") formulation team. Rodan + Fields will be
the first to market for a consumer product utilizing TFC-1067 for
the treatment of dyschromia (hyperpigmentation or "dark spots" of
the skin).
Using the services and expertise of Contract Research
Organization, Roowin SA, Sirona scaled-up production to the
multi-kilogram level. The synthetic process was refined to yield a
large supply of high purity TFC-1067 to meet the exacting standards
for a high-quality product. Roowin will be providing a further
supply of TFC-1067 near term as production continues. Sirona
management is currently in advanced negotiations with Chinese
producers regarding large scale manufacturing of TFC-1067 and
expects to sign an agreement in this regard within the next
quarter. Part of the strategic plan is to build up an inventory of
commercially ready TFC-1067 through two manufacturing sites. This
will enable a quick response to anticipated demands from other
companies using a diversified supply channel. Further details of
the product launch will remain confidential for strategic
reasons.
Sirona also announces a successful attendance at BIO Digital,
June 8-12, 2020. Interest in TFC-1067
and anti-aging from international cosmetic companies was high
during the virtual conference. The advancement of TFC-1067 through
clinical and manufacturing has established a significant level of
interest as the compound is much more attractive to companies.
Having a ready supply of inventory and established manufactures
vastly decreases the risk for organizations looking to add TFC-1067
to their product lines.
About Rodan + Fields
Founded by Stanford-trained
dermatologists Dr. Katie Rodan and
Dr. Kathy Fields, Rodan + Fields was
launched in 2002 with the mission of giving consumers the best skin
of their lives. The brand is a result of the Doctors' belief that
healthy skin empowers people to feel confident. Born in the digital
era and designed to directly reach consumers where they live and
shop via mobile and social networks, Rodan + Fields is disrupting
the industry with its regimen-based skincare and powerful
Independent Consultant community.
For more information, please visit www.rodanandfields.com.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.